Photo by nampoh from unsplash
Brodalumab, a fully human anti‐interleukin‐17 receptor A monoclonal antibody, has demonstrated superior efficacy and safety over ustekinumab as induction therapy for moderate‐to‐severe psoriasis. Click to show full abstract
Brodalumab, a fully human anti‐interleukin‐17 receptor A monoclonal antibody, has demonstrated superior efficacy and safety over ustekinumab as induction therapy for moderate‐to‐severe psoriasis.
Keywords:
safety brodalumab;
efficacy safety;
brodalumab patients;
brodalumab;
psoriasis
Journal Title: British Journal of Dermatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Dermatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!